Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth Hormone in Obese COVID-19 Patients
NCT04532554Phase 4Withdrawn
- Sponsor
- ClinAmygate
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Growth hormone with Placebo (2 arms). Primary endpoint: Need for hospitalization. Planned start Oct 2020; status: withdrawn.
02
Drugs
somatropin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04532554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532554.